We assessed the extent to which the 1998 European guideline goals were reached among patients on statin treatment.
Design
A cross-sectional study.
Methods
A total of 683 consecutive patients on statin treatment were recruited from 48 primary healthcare centres all over Sweden. Serum lipid levels and possible goal-reaching determinants were registered.
Results
The treatment goal for total cholesterol was met in 55% of patients and for low-density lipoprotein cholesterol in 60% of patients. Male sex and a history of diabetes mellitus or cardiovascular disease increased the likelihood of meeting treatment goals.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S).Lancet1994; 344: 1383–1389.
2.
ShepardJCobbeSMFordIIslesCGLorimerARMacfarlanePW. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.N Engl J Med1995; 333: 1301–1307.
3.
Heart Protection Study Collaboration Group. MRC∖BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet2002; 360: 7–22.
4.
BeermanB.New recommendations on the treatment of hyperlipidaemia [in Swedish], vol 3. Uppsala: Medical Products Agency; 1995. pp. 178–203.
5.
WoodDDe BackerGFaergemanOGrahamIManciaGPyöräläK.Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.Atherosclerosis1998; 140: 199–270.
6.
Task force report. Medical Product Agency's recommendations.Uppsala: Medical Products Agency; 2003.
7.
FriedewaldWTLevyRIFredricksonDS.Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin Chem1972; 18: 499–502.
8.
EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries.Lancet2001; 357: 995–1001.
9.
BowkerTJClaytonTCInghamJMcLennanNRHobsonHLPykeSD. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).Heart1996; 75: 334–342.
10.
KahanTWandellP.Risk factors in established coronary heart disease: evaluation of a secondary prevention programme.J Cardiovasc Risk2001; 8: 1–8.
11.
MajumdarSRGurwitzJHSoumeraiSB.Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease.J Gen Intern Med1999; 14: 711–717.
12.
ValeMJJelinekMVBestJD.How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000.Med J Aust2002; 176: 211–215.
13.
EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme.Eur Heart J2001; 22: 554–572.
14.
WandellPEGåfvelsC.Metabolic control and quality of data in medical records for subjects with type 2 diabetes in Swedish primary care: improvement between 1995 and 2001.Scand J Prim Health Care2002; 20: 230–235.
15.
PrimatestaPPoulterNR.Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey.BMJ2000; 321: 1322–1325.
16.
WrightDJGraysonADJacksonMDaintyC.The reality of treating dyslipidaemia in patients with coronary heart disease: a primary care survey.Int J Clin Pract2003; 57: 459–460.
17.
SvilaasARisbergKThoresenMOseL.Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.Am J Cardiol2000; 86: 1250–1253.
18.
Hippisley-CoxJCaterRPringleMCouplandC.Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices.BMJ2003; 326: 689–693.
